Condition
Broader IBD news covering Crohn's disease, ulcerative colitis, research, treatments, monitoring, and patient care.
Page 4 of 87 · 4164 articles
Phase 2a data suggest a combo approach may improve endoscopic remission versus Skyrizi alone, which could matter for future Crohn's treatment options and for patients who have failed prior advanced therapies.
This trial explores whether delivering sodium propionate directly to the colon can alter the gut microbiome and immune markers in people with Crohn’s disease and whether it offers similar or added benefits compared with...
Dietary patterns, especially ultra-processed food intake, are increasingly linked to Crohn's disease activity. This trial could provide randomized evidence on whether reducing ultra-processed foods prolongs remission in...
This trial is testing a novel stem-cell infusion approach aimed at treating Crohn’s disease and ulcerative colitis, so people with IBD may be interested in emerging cell-therapy options and safety data. Phase 1 studies...
An oral biologic study could offer a new treatment approach for people with moderate–severe ulcerative colitis; the trial is evaluating safety and multiple measures of disease activity including endoscopy and histology.
The study focuses on children newly diagnosed with Crohn's disease who start anti-TNF treatment and aims to identify biological and clinical markers tied to complete intestinal healing after one year; results could help...
Cure8 found this source from app.dealroom.co, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Fistula. Open the original article for the full details.
New Phase 2a data suggest a two‑drug combo from AbbVie may produce higher endoscopic remission than Skyrizi alone, which could matter for future treatment options and for patients who have failed prior advanced...
This preclinical study suggests a plant extract reduced inflammation and oxidative stress in a mouse model of ulcerative colitis and proposes molecular targets — an early step toward potential new treatments or research...
Biomarkers of gut barrier integrity and oxidative stress could reveal hidden inflammation, help predict disease progression, and indicate likely treatment response—steps toward more personalized IBD care.
Researchers identified a plant-derived compound that reduced inflammation, oxidative stress, and gut dysbiosis in a mouse model of ulcerative colitis; this could point to new mechanistic leads for future therapies...
The study identifies a new monocyte-surface RNA (Y RNAs) that appears higher in an exploratory IBD cohort and amplifies inflammatory signalling in cells and mice, which could point to new biomarker or therapeutic...
An unusual craving to smell non-food substances (desiderosmia) can be a clue to severe iron deficiency anaemia and may point to undiagnosed inflammatory bowel disease in adolescents. Recognising this sign could speed...
The paper points out that reused patient records and preprocessing choices can change how well gene-expression models appear to predict infliximab response. That matters because such biases could mislead researchers and...
The review identifies PPARγ as a key molecular hub in ulcerative colitis and compiles preclinical evidence that natural compounds can modulate PPARγ-related networks—suggesting possible new therapeutic directions that...
Patients on or considering infliximab may be interested because the paper identifies a possible molecular reason some people don’t respond and tests strategies that could, in principle, improve response to infliximab.
Intestinal fibrosis and strictures are a major unmet need in Crohn’s disease because current anti-inflammatory drugs often don’t reverse established scarring. A drug that limits or reverses fibrosis could reduce the need...
This preclinical study suggests clarithromycin may reduce colon inflammation in ulcerative colitis models and identifies Kv1.3 and the Th17/Treg balance as possible mechanisms — findings that could guide future...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Crohn's disease, and Inflammatory bowel disease. The original article is from Lipids in Health and Disease.
Updated treat-to-target recommendations affect how inflammation and symptoms are monitored and when treatments should be changed. Clear targets and timing help patients and clinicians make consistent, evidence-informed...
People with UC and their clinicians often consider infection risks when choosing biologic therapy. This study examines whether vedolizumab and anti‑TNF drugs differ in risk for C. difficile infection, a relevant...
This study looks directly at whether failing multiple biologic drugs before elective subtotal colectomy affects short-term surgical outcomes for people with ulcerative colitis — information that can help patients and...
MMF-associated enterocolitis can look like other serious causes of colitis and may be underrecognized in lung transplant patients. Correctly identifying MAE can avoid misdiagnosis and inappropriate treatments.
Perianal fistulas are a common, challenging Crohn's complication that often need combined medical and surgical care; understanding local practice patterns helps patients and clinicians anticipate typical treatments and...
Patients and clinicians worry isotretinoin might trigger flares in people with existing IBD. This study suggests that among patients with stable, well-controlled Crohn's or UC, isotretinoin did not generally worsen...
Families and clinicians often wonder whether H. pylori infection in childhood affects risks for asthma, IBD, celiac disease, or other immune-mediated disorders.
This review compiles preclinical evidence that propolis (a natural bee product) reduced inflammation and improved gut barrier and microbiota in animal models of colitis, so it may be a candidate for future clinical...
This preclinical study suggests a food-derived peptide formulation might reduce inflammation and improve intestinal barrier markers in lab and mouse models of ulcerative colitis, which could interest people exploring new...
Based on the title and source metadata, this appears to be a patient education related to Inflammatory bowel disease and Research and clinical trials. The original article is from International journal of nanomedicine.
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease and Tests and monitoring. The original article is from Przegla̜d Gastroenterologiczny.
This study identifies a compound that improved inflammation, barrier integrity, and microbiome/metabolite signatures in a mouse model of ulcerative colitis—areas that matter for symptom control and disease biology in...
This study highlights a potential microbiome–bile acid–immune pathway that could be relevant to ulcerative colitis and suggests a traditional herbal formula may influence that pathway in mice. Patients interested in...
The study offers a validated tool to estimate risk of postoperative recurrence after ileocolonic resection and shows that postoperative biologic prophylaxis markedly lowers early endoscopic recurrence—information that...
Identifying a blood biomarker that appears before symptoms could help find people at higher risk for Crohn’s disease and improve understanding of early disease processes. This could inform earlier monitoring or future...
A blood biomarker that predicts anti-TNF response could help people with IBD and their clinicians choose the right biologic sooner, avoiding ineffective treatment. This study reports that lower baseline serum oncostatin...
People with ulcerative colitis may be interested because the study suggests a combined probiotic approach could strengthen gut bacteria functions linked to a protective metabolite (spermidine) and reduce colitis-like...
A preclinical mouse study found that heat-inactivated Lacticaseibacillus paracasei PC-01 reduced colitis signs and altered gut microbiota, which may be of interest for microbiome-targeted IBD research but does not show...
A new dual-targeting combination (IL-23 + α4β7) showed higher endoscopic remission rates than either drug alone in a Phase IIa Crohn's study, suggesting a potential new approach for patients who need better mucosal...
Cure8 could only read part of this source from finance.yahoo.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab.
Cure8 found this source from youtube.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab. Open the original article for the full details.
Based on the title and source metadata, this appears to be a market or business news related to Crohn's disease, Inflammatory bowel disease, and Risankizumab. The original article is from firstwordpharma.com.
Early antibody signatures could allow earlier identification of people at higher risk for Crohn’s disease or ulcerative colitis, which might eventually enable closer monitoring or preventative research.
Narrowing (stenosis) can cause obstructive symptoms and often leads to surgery; evidence that a biologic—guselkumab—may improve non-passable stenosis and reduce fibrosis-associated biology could affect treatment planning...
Early Phase 2a data suggest a dual-target IBD therapy (ABBV-466) produced higher endoscopic remission than single-pathway agents, which could matter if later trials confirm better outcomes for people with...
Cure8 found this source from pluang.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab. Open the original article for the full details.
This mid-stage trial suggests a dual-targeting combo may improve endoscopic remission rates in Crohn’s disease compared with IL-23 inhibition alone, which could influence future treatment options and company strategies...
This preclinical study identifies a parasite-derived fluid that reduced inflammation, oxidative stress, and microbiome disruption in a mouse model of ulcerative colitis and in intestinal cells, pointing to possible new...
Perianal fistulas are a common, debilitating complication of Crohn’s disease; longer-term data on treatments that can produce durable fistula remission are directly relevant to patients and clinicians managing this...
